WALTHAM, Mass., June 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 8:40 a.m. ET.
A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the CSF-1 receptor. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax ContactSharon KlahreSyndax Pharmaceuticals, Inc.sklahre@syndax.comTel 781.684.9827
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-goldman-sachs-45th-annual-global-healthcare-conference-302163121.html
SOURCE Syndax Pharmaceuticals, Inc.